

HOW INTELLIGENCE INFORMS PEER REVIEW

William Allum
Chair
Upper GI Clinical Reference Group
NCIN

National Cancer Peer Review What is it?



- Quality Assurance process
 - clinical
 - · patient experience
 - · quality of life
 - dignity
 - service commissioning
- · Integral part of Improving Outcome
 - catalyst for change

Background to National Cancer Peer Review Programme



Standards/measures

- First national 'standards' published in 2001
- ▶ Major revision as 'measures' in 2004
- Ongoing updating and extension as new national guidance becomes available (e.g. NICE Improving Outcomes Guidance)
- ▶ Revision in 2008
 - reduction in number of measures with removal of levels
 - revision of measures; some more challenging

Methodological changes introduced for 2009/2010 NCPR



The peer review programme consists of four key stages:

Peer Review

Visits

Targeted

External Verification

Sampled

Internal Validation

All teams except those identified for a visit

Annual Self Assessment

All teams



What has Peer Review achieved?

National Cancer Peer Review Reports




- IOG Measures and Standards
- Team Structure
- Team Function
- Centre / Unit Facilities


Overall compliance per MDT tumour site



Fig: Overall compliance ranges per tumour site Peer Review 04 - 08 Adjusted

Overall Compliance Ranges by MOT Tumous Site (New Review 64 - 68 Adjusted)





Upper GI Outcomes against the Measures - 2011-12



Teams Compliance	SA	IV	PR
100%	0	0	0
90-99%	9	0	0
80-89%	13	1	2
70-79%	6	1	2
60-69%	0	0	2
50-59%	0	0	1
40-49%	0	0	0
0-39%	0	0	0
Median		85%	
Range		52-97%	
Interquartile Range		79-88%	

Oesophago-Gastric Specialist Teams Good Practice - 2011-12



- Availability of minimally invasive and laparoscopic surgery
- Introduction of nurse led clinics
- Availability of EUS
- Increase of availability of specialist dietetic advice
- Increased contribution to the AUGIS dataset

Oesophago-Gastric Specialist Teams Immediate Risks and Serious Concerns - 2011-12



- · No formal 24 hour on-call
- Endoscopic Ultrasound Service (EUS) availability
- No radiology access to images prior to discussion at SMDT
- · Communication and pathways between local and specialist teams
- Lack of dietetic support
- Data collection
- Number of surgeons leading to too few procedures per surgeon
- Lack of cover for gastroenterologist
- Surgery undertaken at local units without IOG arrangements
- CNS support; Oncology support; Gastroenterology support, no dietician cover, no palliative care (all one MDT)



Problems with Peer Review



- Huge burden of structure and process
- Resource intensive process
- · Limited outcome data
- Box ticking exercise
- Limited feedback to clinicians

Clinical Lines of Enquiry



- Clinical Indicators
- National and Local Data on Indicators
- Focus process on good clinical outcomes

Principles of Clinical Indicators



- The data should available nationally or readily available locally. Not intended to require further audit in themselves
- Metrics which can be used as a lever for change and for reflection on clinical practice and outcomes
- They may be lines of enquiry around clinical practice, or around collection of data items, rather than enquiry focused on the data itself
- May cover key stages along the patient pathway, including diagnosis, treatment and follow up
- There should be some consensus on national benchmarking data which can be used to inform the discussions

Data Sources




- Hospital Episode Statistics (HES)
- National Cancer Services Analysis Team
- National Cancer Waits
- National Cancer Data Repository
 - Cancer Registry
 - UK Cancer Information Service
- National Specialty Audits
- National Cancer Research Institute

Centre Workload



- Activity number of new patients referred annually and number discussed at MDM
- Approaches to data recording methodology for recording National Core Data Set
- Involvement in National and local Audit approaches to data entry and evaluation
- Rates of trial entry



Overall Incidence



	Oe	esophageal cancer		Stomach cancer							
		(ICD10 C15)			(ICD10 C16)	10 C16)					
	Number of cases	Percentage	England %	Number of cases	Percentage	England %					
Persons	151			141							
Males	101	66.9%	66.9%	85	60.3%	65.3%					
Females	50	33.1%	33.1%	56	39.7%	34.7%					
Age group											
0-59	32	21.2%	17.3%	28	19.9%	14.7%					
60-69	32	21.2%	26.1%	20	14.2%	19.4%					
70-79	43	28.5%	29.1%	56	39.7%	32.8%					
80+	44	29.1%	27.5%	37	26.2%	33.2%					

Age Distribution for Oesophageal and Gastric Cancer London Cancer Alliance



	OESOPHAGEAL			GASTRIC	GASTRIC					
	< 60	60-69	> 70	< 60	60-69	> 70				
NW	29.1%	27.6%	43.3%	21.6%	23.5%	54.9%				
sw	21.2%	21.2%	57.6%	19.9%	14.2%	65.9%				
SE	16.8%	24.8%	58.4%	24.1%	16.3%	60.6%				
England	17.3%	26.1%	56.6%	14.7%	19.4%	65.9%				

Routes to Diagnosis Gastric Cancer



	WLCN	SWCLN	SELCN	ENGLAND
Two Week Rule	7%	14%	18%	23%
GP / OP Referral	22%	25%	19%	17%
Emergency	32%	35%	41%	33%
Other OP	11%	7%	8%	8%
Inpatient Elective	13%	8%	7%	13%
Death Certificate	1%	1%	1%	1%
Unknown	14%	10%	7%	5%
No. of cases	359	411	476	18,613



National Oesophago – Gastric Cancer Audit









Data collected



- Data on all patients:
 - Referral route
 - Date of diagnosis, staging investigations
 - Planned treatment
- Other data depends on treatment received:
 - Curative and palliative surgery
 - Endoscopic / radiological palliative therapy
 - Chemotherapy / radiotherapy
 - Post-operative pathology after curative surgery


Centre Services



- Diagnostics / Staging availability of PET-CT; MRI; EMR; pancreas biopsy cytology / histology
- Audit of preoperative staging compared with intraop and postop findings: prediction operability (open and close rates; bypass rates when resection planned)
- Pathology review following surgery
- Dietician support

Proportion of Patients who had CT-Scan






Treatment Planning




- · Rates of radical and palliative treatment
- · Radical resection rates; multimodality treament
- Palliative use of chemotherapy and/or radiotherapy
- · availability of novel palliative interventions eg cyber knife
- availability of non-surgical treatments eg radiofrequency ablation liver mets and Barrett's
- rates of best supportive care only; community links
- · use of stents

Oeosophageal and Gastric Resections by Network







Treatment Planning



- Surgeon volume
- Morbidity and mortality (reoperation rates, anastomotic leak rates)
- Number of lymph nodes resected
- Resection margins

Outcomes



Oesophagectomy	Open (n = 783), %	MI (n = 314), %
30 – day mortality	3.1	3.4
Anastomotic Leak	7.8	10.6
Re-operation	10.7	12.4

Gastrectomy	Open (n = 641), %	MI (n = 96), %
30 – day mortality	4.2	4.2
Anastomotic Leak	6.3	9.4
Re-operation	8.0	7.1

National OG Cancer Audit Morbidity and Mortality



	Audit										
	Case Ascert	ainment	Mortality*					Reoperation	1	Anastomoti	c leak
	Expected	Patients		30 day mor	tality	90 day mor	tality				
	cases over 21 month period	with a tumour record	Number of patients	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted
The Royal Marsden NHS Foundation Trust (Specialist Centre)	100 to 200	103	84	0.0%	0.0%	0.0%	0.0%	7.1%	7.0%	4.8%	4.8%
Epsom and St Helier University Hospitals NHS Trust (Local)	100 to 200	60									
Kingston Hospital NHS Trust (Local)	<100	56									
Mayday Healthcare NHS Trust (Local)	<100	74									
St George's Healthcare NHS Trust (Local)	<100	62									

Survival



- Radical treatment: 1,2 and 5 year
- Palliative treatment: 6 and 12 mo and median
- admissions after palliative treatment (number and length of stay)
- patient reported outcomes

Survival Oesophageal Cancer





Cohort analysis of relative survival (RS)


One-, two-, and five-year relative survival (RS) (%) with 95% confidence interval by cancer network of residence and sex.

Oesophageal cancer (ICD10 C15)

	One-year survival Two						vo-yea	r surviv	/al		Five-year survival							
	Period of diagnosis 2004-2008						Period of diagnosis 2003-2007					07	Period of diagnosis 2000-2004					
	followed up until end of 2009						fe	ollowe	d up uı	ntil end	of 200)9	fe	followed up until end of 2009				9
Survival	Males Females				s		Males		ı	emale	s		Males Females				s	
	RS	LCI	UCI	RS	LCI	UCI	RS	LCI	UCI	RS	LCI	UCI	RS	LCI	UCI	RS	LCI	UCI
South West London	42.0	37.0	47.0	43.6	36.4	50.9	25.2	20.6	29.8	24.4	18.0	30.8	14.0	10.3	17.7	18.0	12.2	23.9
England	43.3	42.5	44.0	37.8	36.8	38.8	23.8	23.2	24.5	20.8	19.9	21.7	12.3	11.8	12.9	12.5	11.8	13.3







Conclusions



- · Wealth of data
- NCPR
- Commissioning Specialist Services
- Improve Outcomes